Quoin Pharmaceuticals (Quoin Pharmaceuticals) EBITDA Margin % : 0.00% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Quoin Pharmaceuticals EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Quoin Pharmaceuticals's EBITDA for the three months ended in Mar. 2024 was $-2.43 Mil. Quoin Pharmaceuticals's Revenue for the three months ended in Mar. 2024 was $0.00 Mil. Therefore, Quoin Pharmaceuticals's EBITDA margin for the quarter that ended in Mar. 2024 was 0.00%.

Quoin Pharmaceuticals EBITDA Margin % Historical Data

The historical data trend for Quoin Pharmaceuticals's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Quoin Pharmaceuticals EBITDA Margin % Chart

Quoin Pharmaceuticals Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

EBITDA Margin %

Quoin Pharmaceuticals Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBITDA Margin %	Get a 7-Day Free Trial												-	-	-	-	-

Competitive Comparison of Quoin Pharmaceuticals's EBITDA Margin %

For the Biotechnology subindustry, Quoin Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Quoin Pharmaceuticals's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Quoin Pharmaceuticals's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Quoin Pharmaceuticals's EBITDA Margin % falls into.

Quoin Pharmaceuticals EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Quoin Pharmaceuticals's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-8.583	/	0
	=	%

Quoin Pharmaceuticals's EBITDA Margin % for the quarter that ended in Mar. 2024 is calculated as

EBITDA Margin %	=	EBITDA (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	-2.433	/	0
	=	%

Quoin Pharmaceuticals (NAS:QNRX) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Quoin Pharmaceuticals EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of Quoin Pharmaceuticals's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Quoin Pharmaceuticals (Quoin Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Quoin Pharmaceuticals Ltd (NAS:QNRX) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

42127 Pleasant Forest Court, Ashburn, VA, USA, 20148-7349

Website

https://www.quoinpharma.com

Quoin Pharmaceuticals Ltd is a pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

Executives

Dennis Langer	director	C/O PETER TSOFLIAS, BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHA PA 19103
Michael T Sember	director	AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 671101
Joseph Patrick Cooper	director	PETER TSOFLIAS, C/O BLANK ROME LLP, ONE LOGAN SQUARE, FL 9, PHILADELPHIA PA 19103
Anthony James Culverwell	director	C/O QUOIN PHARMACEUTICALS, LTD., AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101
Gordon Dunn	officer: Chief Financial Officer	AZRIELI CENTER, ROUND TOWER, TER AVIV L3 6701101
Denise P. Carter	director, officer: Chief Operating Officer	AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 9701101
Leong Natalie Ee Mun	director	AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101
Michael Myers	director, officer: Chief Executive Officer	AZRIELI CENTER, ROUND TOWER, 30TH FLOOR, TEL AVIV L3 6701101